Alpha Healthcare Acquisition Corp. AHAC
10.96 +10.96
Day range unavailable
52-week range unavailable
- Market cap
- 140.89M
- Shares out
- 10.36M
- Analysts
- Buy
- Price target
- 19.00 (+73.4%)
No chart data for this range yet.
Key statistics
- Enterprise value
- 140.51M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 28.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 383.40K
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 10.21%
- 50-day average
- 10.01
- 200-day average
- 10.51
Analyst view
Consensus: buy
Buy
Price target (mean) 19.00 +73.4% upside
Now 10.96
- Target (low)
- 18.00
- Target (mean)
- 19.00
- Target (high)
- 20.00
Ratings (-1m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.56.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 20, 2021 | Benchmark | init | — | Buy |
| Apr 9, 2021 | Lake Street | init | — | Buy |
About Alpha Healthcare Acquisition Corp.
As of August 26, 2021, Alpha Healthcare Acquisition Corp. was acquired by Humacyte, Inc., in a reverse merger transaction. Alpha Healthcare Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
News
The Past Week's Notable Insider Buys: Callon Petroleum, Cricut, Krispy Kreme And More 
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp. 
Stocks That Hit 52-Week Lows On Thursday 
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination 
EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack' 
2 SPAC Stocks That Could Be 10-Baggers 
Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021 
Humacyte: Disrupting The Organ Transplant Industry 
40 Stocks Moving in Thursday's Pre-Market Session 
Stocks That Hit 52-Week Highs On Monday
Your note
Sign in to keep a note on AHAC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Maven Securities Limited | 4.83% | 500,000 | 5.09M | Jun 29, 2021 |
| Tudor Investment Corporation | 3.89% | 402,795 | 4.10M | Jun 29, 2021 |
| UBS O'Connor LLC | 2.90% | 300,000 | 3.06M | Jun 29, 2021 |
| Altium Capital Management, LP | 2.66% | 275,000 | 2.80M | Jun 29, 2021 |
| Cowen and Company, LLC | 2.32% | 240,690 | 2.45M | Jun 29, 2021 |
| Alpine Global Management, LLC | 2.03% | 209,743 | 2.14M | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ETF Series Solutions-Morgan Creek-Exos SPAC Originated ETF | 0.15% | 15,549 | 158.44K | Jun 29, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 4,212 | 42.92K | Jun 29, 2021 |